Legal 500
Log in or register
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Legal 500 Trust Centre
  • Contact Us
  • home
  • Market Intelligence
  • Search

7,150 results found

Use advanced search filters to refine your search

2 filters applied

Advanced search filters

Topics
Countries
Contributor

Start typing to add contributors

Content type
Show options
  • Article

    Draft Guidances On Deciding When To Submit A 501(k) For A Change To An Existing Device

    For more information, see FDA's press release announcing the updated recommendations. Comments on both guidances are due November 7, 2016.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    Eliminating Disease-Carrying Pests And Restoring Enjoyment Of The Great Outdoors (Trump EO Tracker)

    Directs federal agencies to implement a nationwide strategy to reduce tick and invasive mosquito populations through land management, biotechnology-enabled pest control...
    United StatesFood, Drugs, Healthcare, Life Sciences
Akin
Akin
  • Article

    FDA's 2016 Budget Request Focuses On Biosimilars, Food Safety, And Drug Compounding

    FDA Commissioner Margaret Hamburg testified regarding the agency's $4.9 billion request, focused on biosimilars, food safety, and drug compounding.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA Announces 2014 Food Safety Challenge

    FDA announced the 2014 FDA Food Safety Challenge, a prize competition under the America COMPETES Reauthorization Act of 2010.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA Announces Plan To Encourage Voluntary Updating Of Drug And Biologics Labels

    As mentioned on our Health Industry Washington Watch blog, the U.S. Food and Drug Administration (FDA) has announced a plan intended to incentivize manufacturers to voluntarily update their prescription drug and biologics labels.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Reed Smith
    Reed Smith
  • Article

    FDA Announces Public Workshop On Sequencing Quality Control 2

    In the May 31, 2016, Federal Register, FDA announced an upcoming public workshop called "Sequencing Quality Control II."
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA Approves Genentech's VABYSMO For Wet AMD And Diabetic Macular Edema

    On January 28, 2022, the Food and Drug Administration (FDA) approved Genentech's VABYSMO (faricimab-svoa) for the treatment of wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    FDA Approves Moderna's MRESVIA Vaccine

    On May 31, 2024, Moderna announced that the FDA has approved its respiratory syncytial virus vaccine ("RSV"), mRESVIA (mRNA-1345).
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    FDA Approves Samsung's Eculizumab Biosimilar

    Samsung Bioepis ("Samsung") announced on July 22 that the FDA approved its BLA for EPYSQLI, an eculizumab biosmilar referencing Alexion's SOLIRIS. EPYSQLI has been approved for the treatment of patients...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    FDA Approves VABYSMO (Faricimab) For Retinal Vein Occlusion

    On October 26, 2023, Genentech, a member of the Roche Group, announced that the FDA approved VABYSMO (faricimab-svoa) for the treatment of macular edema following retinal vein occlusion (RVO).
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    FDA, CDC, And USDA Partner To Develop Improved Method For Identifying Sources Of Foodborne Illness

    FDA and other agencies recently announced the development of an improved method for analyzing outbreak data to trace the cause of foodborne illness caused by the four major foodborne bacteria.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA Final Guidance On Nonproprietary Names Of Biological Products

    In January, 2017, the FDA released a final guidance document outlining its rules for giving nonproprietary names to biological products.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Fish & Richardson PC
    Fish & Richardson PC
  • Article

    FDA Issues Final Orders Classifying And Reclassifying Gastroenterology–Urology Devices Into Class II

    FDA reclassified implanted blood access gastroenterology–urology devices from Class III into Class II (special controls).
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA Issues Final Rule Amending Postmarketing Safety Requirements For Drugs And Biologics

    The new requirement will help FDA more quickly review postmarketing safety reports, identify emerging safety problems, and disseminate safety information.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA Issues Guidance For Unique Device Identification System

    In a follow-up to a final rule issued in September 2013 FDA has issued a small entity compliance guidance on the Unique Device Identification System.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA Meeting On Biomarker Development (Sept. 5)

    On September 5, 2014, the FDA is holding a public meeting at the Washington Plaza Hotel, in Washington DC, to discuss current scientific and regulatory approaches to biomarker development, acceptance, and utility in the development of therapeutic products (e.g., drugs and biologics).
    United StatesFood, Drugs, Healthcare, Life Sciences
    Reed Smith
    Reed Smith
  • Article

    FDA Partners With Foreign Regulators On Global Drug Quality Initiative

    FDA unveiled a new global pharmaceutical quality initiative, strengthening programs with the European Medicines Agency to allow for the inspection of overseas facilities.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA Proposes Removal Of Duplicative Biologics Requirements In Regulations

    FDA proposed an amendment to the biologics regulations that would remove the general safety test requirements for biological products.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA Reaffirms Distinction Between Fluoropolymers And PFAS Of Concern

    On September 1, 2026, the Food & Drug Administration (FDA) reinforced its prior conclusion that fluoropolymers used in medical devices are safe and materially different from the per- and polyfluoroalkyl substances (PFAS) that drive most regulatory, litigation and public health concerns
    United StatesFood, Drugs, Healthcare, Life Sciences
    Akin
    Akin
  • Article

    FDA To Host Public Conference On Key Aspects Of Drug And Device Regulations

    The meeting will be available via webcast, but there will not be a transcript available following the meeting.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Showing 261–280 of 7150 results

    PreviousNext
    Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics